Selecting Observation Vs Immunotherapy in Advanced Melanoma
Source: Cancer Network, April 2024
Jonathan Zager, MD, spoke about the use of observation vs systemic immunotherapy to treat patients with stage IIIA and IIIB melanoma.
A recent debate for the 2024 Society of Surgical Oncology (SSO) Annual Meeting focused on whether to surveil or actively treat patients with IIIA/IIIB melanoma, according to Jonathan Zager, MD.
Zager, chief academic officer, surgical oncologist, and senior member in the Departments of Cutaneous Oncology and Sarcoma at Moffitt Cancer Center, spoke with CancerNetwork® about the potential benefit that surveillance might have over systemic therapy.